S&P DJI Announces March 2021 Quarterly Rebalance
Filed with ASX · · 9 pages · English
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Appendix 4E - Results for announcement to the market
- Shareholder update - year ended 31 December 2020
- Czech Republic Grants National Authorisation for TLX591 Kit
- Appendix 4C and Activities Report for December 2020 Quarter
- New Drug Submission filed with Health Canada for TLX591-CDx
Later from Telix Pharmaceuticals
- TGA commences priority evaluation process for Illuccix
- Launch of International NOBLE Registry for SPECT Imaging
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
- Activities Report and App 4C for quarter ended 31 March 2021
- Phase III Prostate Cancer Therapy Clinical Trial Commences
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals